Results 171 to 180 of about 5,574,472 (302)
US market risk premium used in 2011 by professors, analysts and companies: A survey with 5.731 answers [PDF]
The average Market Risk Premium (MRP) used in 2011 by professors for the USA (5.7%) is higher than the one used by analysts (5.0%) and companies (5.6%). The standard deviation of the MRP used in 2011 by analysts (1.1%) is lower than the ones of companies
Corres, Luis +2 more
core
The Anatomical Record, EarlyView.Abstract Differences in skull and tooth morphology, stomach contents, and estimated bite force between medium‐to‐large sized (≥100 kg) predatory theropod dinosaurs have long been suspected to correlate with differences in their diets and dietary guilds (e.g., hypercarnivory, piscivory).
Cassius Morrison +9 more
wiley +1 more source
Risk-Sharing Externalities and Its Implications for Equity Premium in an Infinite-Horizon Economy [PDF]
This paper examines asset prices when risk-sharing externalities are incorporated into an infinite-horizon model where consumers are exposed to the endogenous income risks. It is shown that there exist multiple types of equilibria depending on the degree
Hiroaki Ohno
core
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Designing Flood Insurance to Maximize Public Benefits in High-Risk Areas. [PDF]
Risk AnalBourdeau-Brien M +5 more
europepmc +1 more source
Market risk premium used in 2008: A survey of more than a 1,000 professors [PDF]
The average Market Risk Premium (MRP) used in 2008 by professors in the United States (6.5%) was higher than the one used by their colleagues in Europe (5.3%), Canada (5.4%), the United Kingdom (5.6%) and Australia (5.9%).
Fernandez, Pablo
core
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Perpetual Futures for Stocks: The SpaceX Pre-IPO Market. [PDF]
Entropy (Basel)Gupta A, Polson NG.
europepmc +1 more source
The equity premium and the risk free rate in a production economy. A new perspective [PDF]
We study a competitive equilibrium in a production economy, i.e., a system of prices at which firms’ profit maximizing production decisions and individuals’ preferred affordable consumption choices equate supply and demand in every market.
Aase, Knut K.
core
British Journal of Clinical Pharmacology, EarlyView.Aims This study aims to develop a structured list of value assessment criteria for drug repurposing (DR) projects designed to support consistent, evidence‐informed decision‐making by funders. The assessment criteria were developed within the REMEDi4ALL project, a multi‐stakeholder Horizon Europe funded initiative to advance DR and were validated ...
Dalma Hosszú +10 more
wiley +1 more source